Phase II, Randomized, Double-Blinded, Placebo-Controlled Trial of Extended-Release Niacin (Niaspan) to Augment Subacute Ischemic Stroke Recovery.
Phase of Trial: Phase II
Latest Information Update: 13 Sep 2012
At a glance
- Drugs Niacin (Primary)
- Indications Dyslipidaemias
- Focus Adverse reactions
- 31 Aug 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 19 Jul 2011 Planned end date changed from 1 Dec 2011 to 1 Dec 2012 as reported by ClinicalTrials.gov record.
- 03 Oct 2009 New trial record